Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$599K Hold
2,280
0.38% 41
2022
Q3
$514K Hold
2,280
0.35% 42
2022
Q2
$555K Hold
2,280
0.38% 43
2022
Q1
$551K Hold
2,280
0.33% 44
2021
Q4
$513K Hold
2,280
0.29% 46
2021
Q3
$485K Hold
2,280
0.3% 45
2021
Q2
$556K Hold
2,280
0.35% 45
2021
Q1
$567K Hold
2,280
0.38% 45
2020
Q4
$524K Hold
2,280
0.38% 44
2020
Q3
$578K Hold
2,280
0.5% 39
2020
Q2
$538K Hold
2,280
0.49% 39
2020
Q1
$462K Hold
2,280
0.46% 39
2019
Q4
$550K Hold
2,280
0.42% 41
2019
Q3
$441K Hold
2,280
0.36% 45
2019
Q2
$420K Hold
2,280
0.36% 44
2019
Q1
$433K Hold
2,280
0.37% 44
2018
Q4
$444K Hold
2,280
0.43% 40
2018
Q3
$473K Hold
2,280
0.42% 41
2018
Q2
$421K Hold
2,280
0.38% 44
2018
Q1
$389K Hold
2,280
0.35% 47
2017
Q4
$396K Buy
+2,280
New +$404K 0.33% 46

Other funds holding AMGN

Red Cedar Capital's AMGN Position: Q4 2022 in Review

Red Cedar Capital held its Amgen (AMGN) position steady in Q4 2022 at 2,280 shares worth $599K. The position accounts for 0.38% of the portfolio, ranked #41.

Red Cedar Capital first reported a position in AMGN in Q4 2017 and has held it in 21 quarters since. 2,501 funds tracked by Wall St. Rank hold AMGN as of Q4 2022.

  • Red Cedar Capital held 2,280 shares of Amgen worth $599K as of Q4 2022.
  • Red Cedar Capital left its Amgen share count unchanged in Q4 2022.
  • Amgen made up 0.38% of Red Cedar Capital's portfolio in Q4 2022, its #41 holding.
  • Red Cedar Capital first reported a position in Amgen in Q4 2017 and has held it in 21 quarters since.
  • 2,501 funds tracked by Wall St. Rank held Amgen as of Q4 2022.

Based on Red Cedar Capital's 13F filing for Q4 2022, filed 6 Feb 2023.